$ACER "Acer Therapeutics to Develop Emetine as Potential COVID-19 Treatment in Collaboration with National Center for Advancing Translational Sciences, One of the National Institutes of Health"
Q4 2020 is here, could be announcing the Covid 19 treatment news any day now. Also the other projects that are due Q4 2020. It has to be this week I'd imagine.
• Emetine for the treatment of COVID-19************************
• ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD) • EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation • Osanetant for the treatment of induced Vasomotor Symptoms (iVMS) • Product candidates are believed to present a comparatively de-risked profile, having one or more of: • Favorable safety profile; clinical proof-of-concept data; mechanistic differentiation • Potential expedited paths for development through specific FDA-established programs • Multiple anticipated key milestones: • Emetine animal efficacy study results: Q4 2020 ******************************* • EDSIVO™ request FDA meeting to discuss confirmatory evidence plan: Q4 2020 ********************************** • Emetine IND submission and Phase 2/3 trial initiation*$: H1 2021 • ACER-001 BE fed trial completion: Q1 2021 • ACER-001 pre-NDA meeting with FDA: mid-H1 2021 • ACER-001 (UCD) NDA submission**$: Q2 2021 • Osanetant IND submission: Q2 2021 • Osanetant Phase 1/2 trial initiation*$: H2 2021
News 
Market Data 
Discover 
